Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MeReC Extra 48

The National Prescribing Centre has published MeReC Extra 48 (PDF) which discusses recently published SEARCH study and a meta-analysis that included the SEARCH results.

The SEARCH study compared simvastatin 20mg to simvastatin 80mg over a period of 6.7 years for secondary prevention of cardiovascular events. This study found no significant difference in major vascular events but a higher risk of side effects including myopathy and rhabdomyolysis with the higher dose.

The meta-analysis reviewed the benefits of statin therapy and included the SEARCH results. The review concluded that reductions in LDL cholesterol of 1mmol/L result in a reduction in major cardiovascular events of approximately 20%. They also note that more intensive statin therapy in selected high-risk populations might bring additional benefits.

Action: This new evidence supports the current NICE Lipid Modification guideline. Simvastatin 40mg daily remains the first line choice in the majority of people with higher intensity treatment reserved for consideration in those at higher risk after assessment of risks and benefits.

Share 'MeReC Extra 48' on Email Share 'MeReC Extra 48' on Delicious Share 'MeReC Extra 48' on Digg Share 'MeReC Extra 48' on Facebook Share 'MeReC Extra 48' on Google+ Share 'MeReC Extra 48' on reddit Share 'MeReC Extra 48' on StumbleUpon Share 'MeReC Extra 48' on Twitter

atomic-wealth

No Comments to “MeReC Extra 48”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,208 spam comments.

atomic-wealth
fond-illness
summer